Key statistics
On Friday, Evotec SE (EVT:STU) closed at 8.75, 72.41% above the 52 week low of 5.08 set on Aug 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.78 |
---|---|
High | 8.93 |
Low | 8.69 |
Bid | 8.74 |
Offer | 8.77 |
Previous close | 8.79 |
Average volume | 21.17k |
---|---|
Shares outstanding | 177.76m |
Free float | 158.04m |
P/E (TTM) | -- |
Market cap | 1.54bn EUR |
EPS (TTM) | -0.9668 EUR |
Data delayed at least 15 minutes, as of Feb 14 2025.
More ▼
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-DD: Evotec SE: Dr. Cord Dohrmann, Exercise against Cash Settlement (Share Performance Plan)
- EQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk
- EQS-PVR: Evotec SE: Correction of a release from 27/11/2024 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
More ▼